







Ocrelizumab in MS patients with persistence of disease activity after alemtuzumab: A multi-center Italian study

Caterina Lapucci, Jessica Frau, Eleonora Cocco , Giancarlo Coghe, Maria Petracca , Roberta Lanzillo, Vincenzo Brescia Morra, Carolina Gabri Nicoletti, Dorian Landi, Girolama Marfia, Marco Vercellino, Paola Cavalla , Assunta Bianco, Massimiliano Mirabella , Valentina Torri Clerici, Eugenia Tomas, Maria Teresa Ferrò, Paola Grossi, Agostino Nozzolillo, Lucia Moiola , Mauro Zaffaroni, Marco Ronzoni, Federica Pinardi, Giovanni Novi , Maria Cellerino, Antonio Uccelli and Matilde Inglese

Abstract

Background: The reason why some multiple sclerosis (MS) patients show disease activity after alemtuzumab (ALM) is still unclear, but ocrelizumab (OCR) could represent an interesting sequential therapeutic approach.

Objectives: To investigate safety and efficacy of OCR in MS patients with disease activity after two ALM courses.

Methods: Observational retrospective multi-centers Italian cohort study.

Results: Seventy-two subjects were included. Mean follow-up (FU) was 2.4 (± 1) years. Forty-five patients (62.5%) experienced at least one adverse event (AE), with infections accounting for 96.7% of cases. A reduction in total lymphocytes was observed between OCR start and 6 months FU, driven by BCD19+ lymphocytes depletion ($p < 0.001$). Immunoglobulin M (IgM) levels decreased between OCR start and 6 months FU ($p < 0.001$). At 2-year FU, relapse, magnetic resonance imaging (MRI) activity and disability worsening-free survival were 92.1%, 90.8%, and 89.2%. The evidence of inflammatory activity between the two ALM courses was associated with higher risk of relapse, MRI activity, and NEDA-3 status loss in relapsing-remitting multiple sclerosis (RRMS; $p = 0.02$, $p = 0.05$, $p = 0.01$, respectively).

Conclusions: OCR after two ALM courses seemed to be safe and effective. Early IgM hypogammaglobulinemia occurred in a high proportion of patients. The evidence of inflammatory activity between ALM courses seemed to increase the risk of MS re-activation on OCR treatment.

Keywords: Multiple sclerosis, alemtuzumab, ocrelizumab, induction, therapy, safety, efficacy

Date received: 22 April 2024; revised: 3 June 2024; accepted: 19 June 2024

Introduction

In recent times, there has been a significant shift toward the early employment of high-efficacy therapies in multiple sclerosis (MS) treatment,¹ diverging from the escalating strategy recommended over the last two decades.² Early adoption of induction together with high-efficacy disease-modifying therapies may offer the most favorable risk–benefit profile, particularly for young patients with highly active relapsing-remitting (RR) MS.¹ Among approved drugs, alemtuzumab (ALM) is one of the most effective induction therapies against MS.^{3,4} Data from the

extension phases of ALM clinical trials showed excellent long-term efficacy even if 68% and 60% of patients enrolled in CARE-MS I and CARE-MS II needed a re-treatment with ALM during the 3 years following the last ALM cycle.^{5,6} The reason why some MS patients show persistence of inflammatory disease activity after ALM treatment is still matter of debate. The development of neutralizing antidrug antibodies⁷ does not seem to be sufficient to explain disease persistence after the first two ALM courses. Alternatively, a B-cell driven mechanism has been suggested, particularly in paradoxical disease

Multiple Sclerosis Journal

2024, Vol. 30(9) 1151–1162

DOI: 10.1177/
13524585241266509

© The Author(s), 2024.
Article reuse guidelines:
sagepub.com/journals-
permissions

Correspondence to:
M Inglese
IRCCS Ospedale Policlinico
San Martino, Largo P. Daneo
3, 16132 Genoa, Italy.
m.inglese@unige.it
Caterina Lapucci
Giovanni Novi
IRCCS Ospedale Policlinico
San Martino, Genoa, Italy

Jessica Frau
Giancarlo Coghe
Centro regionale per la
diagnosi e la cura della
Sclerosi Multipla, ASL
Cagliari, Cagliari, Italy

Eleonora Cocco
Centro regionale per la
diagnosi e la cura della
Sclerosi Multipla, ASL
Cagliari, Cagliari, Italy/
Department of Medical
Sciences and Public Health,
Università degli studi di
Cagliari, Cagliari, Italy

Maria Petracca
Department of Human
Neurosciences, Sapienza
University of Rome, Rome,
Italy

Roberta Lanzillo
Vincenzo Brescia Morra
Department of
Neurosciences, Reproductive
and Odontostomatological
Sciences, University of
Naples Federico II, Naples,
Italy

Carolina Gabri Nicoletti
Doriana Landi
Girolama Marfia
MS Center, Tor Vergata
University of Rome, Rome,
Italy

Marco Vercellino
Paola Cavalla
Division of Neurology,
Department of Neuroscience
and Mental Health, City
of Health and Science,
University Hospital of
Torino, Turin, Italy

Assunta Bianco
Multiple Sclerosis Center,
Fondazione Policlinico
Universitario Agostino
Gemelli IRCCS, Rome, Italy

Massimiliano Mirabella
Multiple Sclerosis Center,
Fondazione Policlinico
Universitario Agostino
Gemelli IRCCS, Rome,
Italy/Centro di Ricerca per
la Sclerosi Multipla "Anna
Paola Batocchi," Università
Cattolica del Sacro Cuore,
Rome, Italy

Valentina Torri Clerici
Eugenia Tomas
Neuroimmunology and
Neuromuscular Diseases
Unit, Fondazione IRCCS
Istituto Neurologico Carlo
Besta, Milano, Italy

Maria Teresa Ferrò
Paola Grossi
Neuroimmunology,
Neurological Unit,
Cerebrovascular
Department, Center for
Multiple Sclerosis, ASST
Crema, Crema, Italy

Agostino Nozzolillo
Lucia Moiola
Multiple Sclerosis Center,
Neurology Department,
IRCCS San Raffaele
Hospital, Milan, Italy

Mauro Zaffaroni
Centro Sclerosi Multipla,
Ospedale di Gallarate—
ASST della Valle Olona,
Gallarate, Italy

Marco Ronzoni
U.O. Neurologia, ASST
Rhodense, Garbagnate
Milanese, Italy

Federica Pinardi
IRCCS Istituto delle scienze
neurologiche di Bologna,
UOSI Riabilitazione
Sclerosi Multipla Bologna,
Bologna, Italy

Maria Cellerno
Department of
Neuroscience,
Rehabilitation,
Ophthalmology, Genetics,
Maternal and Child Health
(DINOEMI), University of
Genoa, Genoa, Italy

Antonio Uccelli
Matilde Inglese
IRCCS Ospedale
Policlinico San Martino,
Genoa, Italy/Department
of Neuroscience,
Rehabilitation,
Ophthalmology, Genetics,
Maternal and Child Health
(DINOEMI), University of
Genoa, Genoa, Italy

re-activation, where single case reports described the good outcome achieved after the use of anti-CD20 therapies.⁸ Therefore, very little is known about the immunological mechanisms underlying the persistence of disease activity after ALM, as well as about the development of secondary autoimmune complications,⁹ for which a targeted B-cell depletion strategy has been recently suggested.¹⁰ Furthermore, although a role of ALM in reducing risk of secondary progression has been hypothesized,¹¹ this might be limited to patients showing residual inflammatory activity. In such scenario, treatment with ocrelizumab (OCR) could represent an interesting therapeutic approach.

The aims of this study were to investigate (1) safety and (2) efficacy of treatment with OCR in MS patients who experienced persistence of inflammatory activity and/or disability progression after the first two ALM courses.

Materials and methods

This is an observational retrospective multi-centers cohort study conducted at different MS Centers in Italy. MS patients who started OCR after the first two ALM courses from June 2019 to July 2023 and had at least 6 months follow-up (FU) after OCR initiation was consecutively included. RR and progressive (relapsing and no relapsing, from now on “RP” and “PnoR,” respectively) courses were defined according to Lublin et al.¹² From March to June 2020, due to coronavirus disease 2019 (COVID-19) pandemic, OCR was administered following a tailored approach evaluating the profile risk of each patient, according to international indications.^{13,14} Given the real-life and multi-center nature of the study, in order to minimize the heterogeneity of data, we used the reference values derived from the American Board of Internal Medicine (ABIM)¹⁵ to define when a laboratory variable fell into a pathological range (for TCD4+ normal range: 530–1570 cell/mm³, for TCD8+ normal range: 430–1060 cell/mm³, for BCD19+ normal range: 208–590 cell/mm³, respectively; IgG normal range: 800–1500 g/L, IgA normal range: 90–325 g/L, IgM normal range: 45–150 g/L, respectively).

Study endpoints

The primary objective of our study was to assess safety of OCR treatment after two ALM courses in terms of (1) IARs, (2) infections and cancer, (3) secondary autoimmune events, (4) laboratory changes in lymphocyte profiling, immunoglobulin concentration, thyroid function, and autoimmunity. As IARs are concerned, all OCR patients performed pre-medication

according to the Italian SPC:¹⁶ 100 mg of methylprednisolone (or equivalent) intravenously approximately 30 minutes before each infusion and antihistamine about 30–60 minutes before each infusion. The secondary aims were to determine efficacy of OCR therapy in terms of (1) time-to-first relapse (defined as “new or worsening symptoms attributable to MS, preceded by 30 days of stability, lasting for more than 24 hours, not associated with fever, and leading to ≥ 0.5 EDSS points increase compared to a prior visit or ≥ 2 points increase in one EDSS functional system, or ≥ 1 point increase in two EDSS functional systems (excepting bladder and cognitive changes”),¹⁷ time-to-first evidence of magnetic resonance imaging (MRI) activity (defined as “evidence of new T2/FLAIR lesion/s and/or gadolinium enhancing lesions and/or enhancement of pre-existing T2/FLAIR lesion/s”), time-to-confirmed disability worsening (defined as “an increase of at least 1.5 points for baseline EDSS of 0, an increase of at least 1.0 point if baseline EDSS was 1–5.5 points or an increase of at least 0.5 points if baseline EDSS was > 5.5 points”)¹⁸ and time-to-first evidence of disease activity (according to the NEDA-3 definition); (2) clinical predictors of inflammatory activity (relapse and/or MRI activity) and disability progression during OCR treatment. Routinary clinical evaluations were performed every 3–6 months during OCR FU. Baseline brain MRI (acquired within 3 months before OCR start) was the pre-treatment reference scan. Where available, also data from spinal cord MRIs were used. For the inclusion in this study, at least one brain MRI per year after OCR start was required. Out of the total cohort, 56 (77.8%) patients performed brain MRI every 6 months, 16 (22.2%) performed MRI once a year. Patients who clinically relapsed¹⁷ performed additional brain or spinal cord MRI based on their symptoms. The application of the definition of “relapse,” associated with the careful exclusion of concomitant potentially confounding conditions (fever, metabolic abnormalities . . .),¹⁷ associated with the radiological demonstration of new inflammatory activity at the time of the clinical relapse, minimized the risk of including “pseudorelapses” in this study. All the analyses concerning efficacy aims were performed (1) on the global cohort, and, as sensitivity analysis, (2) on RRMS and (3) on progressive MS (PMS), with the latest one originated from the inclusion of PnoR and RP patients together, thus considering as a whole all patients who showed disability progression.

Statistical analysis

Analysis of covariance (ANCOVA) for repeated measures corrected for gender, age, wash-out between

the second ALM course and OCR start was used to evaluate changes in total lymphocytes, lymphocytes subsets, and immunoglobulin levels between OCR start and 6-, 12-, and 24-month FU (Bonferroni corrected). The probability of relapse-free survival, MRI activity-free survival, disability worsening-free survival, and NEDA-3 status was calculated with the Kaplan–Meier estimator. Univariate and multivariate analyses assessing the association of demographic- and disease-related characteristics with survival endpoints were performed using Cox proportional hazards regression analysis models. A two-sided $p < 0.05$ was used for statistical significance (SPSS 23, IBM; version 23.0).

The Ethics Committee of IRCCS Ospedale Policlinico San Martino (Genoa) approved the study (CE 2460PRNO240220 “Alem-Stop” 73/2020 10344), conducted in accordance with the ethical principles of the Declaration of Helsinki. All participants provided consent to use their medical history for publication.

Data are available upon reasonable request.

Results

Data about 72 consecutive MS patients (57 RR, 10 RP, 5 PnoR) who started OCR after the first two ALM courses were collected. Mean FU from OCR start was 2.4 (± 1) years. Demographic- and disease-related characteristics of patients are reported in Table 1.

Primary aims

Infusion-associated reactions. Ten (13.9%) and 1 (1.4%) out of 72 MS patients developed infusion-associated reactions (IARs) at first and/or second inductive OCR infusion, respectively. None of them was “severe,” 10 were “moderate” ($n=7$ skin rash, $n=3$ headache), and 1 was “mild” (headache) in severity.¹⁹ An antihistamine drug and acetaminophen were administered with rapid and complete recovery. No IARs were notified at following OCR infusions.

Infections. Forty-five patients (62.5%) experienced at least one adverse event (AE) while on OCR therapy. Mean (SD) number of AEs per patient was 1 (1–2). Infections accounted for the vast majority (96.7%) of total AEs. Patients with progressive MS (PnoR + RP) had a slightly increased, although not significant, incidence of AEs (62.8% vs 58.4%). Most patients (84.3%) experienced the first AE within the first year of treatment. In two patients (2.8%), a diagnosis of neoplasm was reported: colic cancer ($n=1$, at +370 days from first OCR course, with no lymph

Table 1. Demographic- and disease-related features of study population.

Patients, n	72
Age at OCR start, mean (SD), years	39.1 (9.2)
Gender, female (%)	63.9
MS phenotype at OCR start, %	
RR	79.2
RP	13.9
PnoR	6.9
DMTs pre-ALM	
Naïve, %	12.5
I-line therapy, %	27.8
Fingolimod, %	40.3
Natalizumab, %	23.6
Cumulative no of relapses after ALM, mean	69
No. of new T2 lesions at MS reactivation after ALM, mean (SD)	3 (3.2)
No. of Gd+ lesions at MS reactivation after ALM, mean (SD)	1 (2)
Time between last ALM and OCR start, mean (SD), months	29 (11.6)
Disease duration at OCR start, mean (SD), years	12.4 (6.7)
FU duration from OCR start, mean (SD), years	2.4 (1)
EDSS at ALM start, median (IQR)	4 (1–8)
EDSS at OCR start, median (IQR)	3.5 (0–8)
Reason of switch to OCR	
Inflammation (relapse and/or MRI activity), n (%)	62 (86.1)
Disability progression, n (%)	10 (13.9%)

OCR: ocrelizumab; MS: multiple sclerosis; RR: relapsing remitting; RP: relapsing progressing; PnoR: progressive no-relapsing; DMT: disease modifying therapy; ALM: alemtuzumab; I line: first line; FU: follow-up; EDSS: Expanded Disability Status Scale; IQR: interquartile range; MRI: magnetic resonance imaging.

nodal or metastatic involvement) and cervical cancer (CIN2 $n=1$, +457 days). Both patients achieved complete remission of their neoplastic comorbidity at their maximum FU (3.2 and 2.8 years, respectively).

No infectious events required hospitalization nor fulfilled other criteria for serious AEs.²⁰

Two patients required hospitalization due to safety issues ($n=1$ for colic cancer, $n=1$ for appendectomy).

AEs and serious AEs are detailed in Table 2.

Secondary autoimmunity. One patient (1.4%) received diagnosis of thyroiditis a few days after the

Table 2. Primary aims: safety.

	Total cohort	RR	PnoR + RP
Any adverse events, <i>n</i> (%)	61 (62.5)	35 (58.4)	26 (62.8)
Serious infusion associated reactions, <i>n</i> (%)	0	0	0
Adverse events leading to OCR discontinuation, <i>n</i> (%)	1(1.4) ^a	1 (1.7)	0
Adverse events leading to hospitalization, <i>n</i> (%)	2 ^b (2.8)	0	2 (13.3)
Number of adverse events per subject, median (IQR)	1 (1–2)	1 (1–2)	1 (1–2)
Pregnancy leading to OCR discontinuation, <i>n</i> (%)	1 (1.4)	1 (1.7)	0
Time from first OCR infusion, days, mean (range)	194 (67–416)	145 (67–404)	221 (68–487)
Infectious adverse events, <i>n</i> (%)	59 (59.7)	40 (56.2)	19 (60.7)
Pneumonia	1	1	0
Upper respiratory tract infection	35	25	10
Lower urinary tract infection	12	8	4
HSV1 reactivation	7	4	3
VZV reactivation	3	2	1
Appendectomy	1	0	1
Neoplasm, <i>n</i> (%)	2 ^c (2.8)	1 (1.7)	1 (6.7)
Death, <i>n</i> (%)	0	0	0

RR: relapsing remitting; PnoR: PnoR: progressive no-relapsing; RP: relapsing progressing; OCR: ocrelizumab; IQR: interquartile range; HSV1: herpes simplex virus type 1; VZV: varicella-zoster virus.

^aColic cancer.

^bColic cancer, appendectomy.

^cColic cancer, cervical intraepithelial neoplasia grade 2 (CIN2).

first inductive OCR infusion. None of the patients developed other autoimmune complications during OCR treatment.

At 6- and 12-month FU, a decrease in the percentage of MS patients who showed thyroid stimulating hormone (TSH) abnormalities (hypo/hyper), anti-TSH antibodies positivity, and anti-TPO antibodies positivity was observed (data available for *n* = 40 patients). Figure 1 shows the percentage of patients with TSH abnormalities, anti-TSH and anti-TPO antibodies positivity at OCR start, 6- and 12-month FU.

Laboratory abnormalities

Lymphocyte profiling. Considering baseline, 6- and 12-month FU after OCR start, data about lymphocyte count were available for 33 (45.8%) MS patients. None of them showed lymphopenia at OCR start. A significant decrease in total lymphocytes count was observed between OCR start and 6 months FU (1648.5 ± 841.2 cell/mm³ vs 1178 ± 392.9 cell/mm³, mean difference = 470.5, 95% CI (97.6, 843.6), *p* = 0.010) and between OCR start and 12 months FU (1648.5 ± 841.2 cell/mm³ vs 1285.6 ± 517.4 cell/mm³, mean difference = 362.9, 95% confidence interval (CI) = [11.3, 714.5], *p* = 0.041).




Figure 1. Proportion of patients with TSH abnormalities, anti-TSH and anti-TPO antibodies positivity at OCR start and during the follow-up.

For TSH (hypo/hyper): 39.1%, 15.1%, 8.7% at OCR start, 6- and 12-months FU, respectively; for anti-TSH antibodies positivity: 22.7%, 9.1%, 8.7% at OCR start, 6- and 12-month FU, respectively; for anti-TPO antibodies positivity: 34.8%, 19%, 17.4% at OCR start, 6- and 12-month FU, respectively. One patient candidate for thyroidectomy after II ALM course who started OCR in the meanwhile due to a severe relapse presented a rapid recovery of thyroid function, and at 6 months FU, also stopped any thyroid-related treatment.

Twenty-four (72.7%) MS patients showed TCD4+ lymphopenia at OCR start (363.2 ± 15.4 cell/mm³). No significant differences in TCD4+ lymphocytes were observed, although a trend toward TCD4+ cells repopulation was evident (OCR start:

448.7 ± 37.5 cell/mm³; 6 months FU: 486.5 ± 33.8 cell/mm³; 12 months FU: 519.8 ± 35.4 cell/mm³).

Eleven (33.3%) MS patients showed TCD8+ lymphopenia at OCR start (165.2 ± 15.4 cell/mm³). No significant differences in TCD8+ lymphocytes were observed (OCR start: 302.1 ± 28.1 cell/mm³; 6 months FU: 324.9 ± 29.9 cell/mm³; 12 months FU: 318.7 ± 28.7 cell/mm³).

None of MS patients showed BCD19+ lymphopenia at OCR start, while 8 (24.2%) showed BCD19+ lymphocytosis. A significant decrease in BCD19+ lymphocytes count was observed between OCR start and 6 months FU (415.9 ± 46.1 cell/mm³ vs 36.8 ± 10.5 cell/mm³, mean difference = 379.1, 95% CI = [264.3, 493.9], $p < 0.001$) and between OCR and 12 months FU (36.8 ± 10.5 cell/mm³ vs 28.3 ± 8.5 cell/mm³, mean difference = 37.6, 95% CI = [269.3, 505.9], $p < 0.001$). This finding was confirmed also MS patients who had BCD19+ lymphocytosis at OCR start ($p < 0.05$).

A subgroup analysis was performed on MS patients in which immunophenotype was available and reached 2-year FU ($n = 16$). A significant increase in TCD4+ and TCD8+ lymphocytes was observed between 12- and 24-month FU (532.5 ± 47.7 cell/mm³ vs 634.1 ± 49.8 cell/mm³, mean difference = 101.6, 95% CI = [-263.1, 59.9], $p < 0.05$ for TCD4+; 328.7 ± 31.7 cell/mm³ vs 429.5 ± 11.7 cell/mm³, mean difference = 100.8, 95% CI = [-259.6, 57.4], $p < 0.05$ for TCD8+). BCD19+ cells depletion was maintained at 24 months FU (no significant differences between 6–12 and 24 months FU; between OCR start and 24 months FU $p < 0.001$).

Immunoglobulin levels. None of the patients showed hypo-IgG, hypo-IgA, nor hypo-IgM at OCR start. No significant differences in IgG and IgA levels were observed at 6- and 12-month FU. A significant decrease in IgM levels was observed between OCR start and 6 months FU (0.9 ± 0.1 g/L vs 0.6 ± 0.1 g/L, mean difference = 0.345, 95% CI = [0.2, 0.5], $p < 0.001$), stable at 12 months FU (0.6 ± 0.1 g/L). At OCR start, 15% patients had hypo-IgM (0.75 ± 0.1 g/L) and 48.1% at 6- and 12-month FU.

Lymphocyte profiling and Immunoglobulins levels are detailed in Table 3 and Figure 2.

No significant correlations between TCD4+, TCD8+ lymphopenia, and Ig (IgG, IgA, and IgM) levels at OCR follow-ups and infection rates were detected. Specifically, 13/58 (22.4%) patients who

developed infectious complications of any type and grade showed TCD4+ or TCD8+ lymphopenia before or at the moment of infection development. As expected, all of them were BCD19+ cells depleted. As Ig levels are concerned, 27/58 (46.6%), 2/58 (3.4%), and 0 (0%) patients who developed infectious complications of any type and grade showed evidence of IgM, IgG, and IgA hypogammaglobulinemia at 6 and 12 months FU after OCR start, respectively.

Secondary aims

Figure 3 (a) to (h) reports the results of the efficacy aims for the whole cohort, RRMS, and PMS (PnoR + RP) separately.

Whole cohort. At 2-year FU, 92.1% of patients were free of relapses (see Figure 3 (a)). At 2-year FU, 90.8% of patients were free of MRI activity (see Figure 3 (b)). At 2-year FU, 89.2% patients were free of disability worsening (see Figure 3 (c)). At 2-year FU, 79.9% of patients achieved NEDA-3 status (see Figure 3 (d)).

Subgroup analysis: RRMS and PMS. At 2-year FU, 92.1% of patients with RRMS were free of relapses. No PMS patients showed relapses during OCR treatment (see Figure 3 (e)). Five RRMS patients had a single relapse at +14, +12, +16, +18, and +10 months from OCR start. Out of them, one patient (EDSS increase +2.5) did not fully recover (6 months confirmed disability increase of +1 EDSS point).

At 2-year FU, 90.8% of patients with RRMS were free of MRI activity. No PMS patients showed evidence of MRI activity during OCR (see Figure 3 (f)). Two RRMS patients (3.5%) showed isolated MRI activity in absence of clinical correlates at +24 and +6 months from OCR start, respectively.

At 2-year FU, 94% of patients with RRMS and 72.7% patients with PMS were free of disability worsening, respectively (see Figure 3 (g)). At 2-year FU, NEDA-3 percentages were 82.1% and 72.7% for patients with RRMS and PMS, respectively (see Figure 3 (h)).

Table 4 reports the results of the univariate and multivariate analyses of clinical factors influencing efficacy for the whole cohort and RRMS subgroup.

In the whole cohort, higher EDSS at OCR initiation and disability worsening after ALM were associated with increased risk of progression during OCR ($p = 0.02$ and $p = 0.005$, respectively). At multivariate

Table 3. Lymphocyte counts and immunoglobulin levels during OCR therapy.

Total cohort	
Baseline	
Available, <i>n</i>	33
Total lymphocytes (cell/mm ³), mean (SD)	1648.52 (841.2)
BCD19+ lymphocytes (cell/mm ³), mean (SD) ^a	415.9 (46.2)
TCD4+ lymphocytes (cell/mm ³), mean (SD) ^b	448.7 (37.5)
TCD8+ lymphocytes (cell/mm ³), mean (SD) ^c	302.1 (28.1)
Available, <i>n</i>	27
IgG (g/L), mean (SD) ^d	8.9 (0.3)
IgA (g/L), mean (SD) ^e	1.9 (0.5)
IgM (g/L), mean (SD) ^f	0.9 (0.1)
6 months	
Available, <i>n</i>	33
Total lymphocytes (cell/mm ³), mean (SD)	1178 (392.9)
BCD19+ lymphocytes (cell/mm ³), mean (SD) ^a	36.8 (10.5)
TCD4+ lymphocytes (cell/mm ³), mean (SD) ^b	486.5 (33.8)
TCD8+ lymphocytes (cell/mm ³), mean (SD) ^c	324.9 (29.9)
Available, <i>n</i>	27
IgG (g/L), mean (SD) ^d	9.3 (0.4)
IgA (g/L), mean (SD) ^e	1.6 (0.1)
IgM (g/L), mean (SD) ^f	0.6 (0.1)
12 months	
Available, <i>n</i>	33
Total lymphocytes (cell/mm ³), mean (SD)	1285.7 (517.4)
BCD19+ lymphocytes (cell/mm ³), mean (SD) ^a	28.3 (8.5)
TCD4+ lymphocytes (cell/mm ³), mean (SD) ^b	519.8 (35.4)
TCD8+ lymphocytes (cell/mm ³), mean (SD) ^c	318.7 (28.6)
Available, <i>n</i>	27
IgG (g/L), mean (SD) ^d	9.2 (0.4)
IgA (g/L), mean (SD) ^e	1.7 (0.1)
IgM (g/L), mean (SD) ^f	(0.1)

OCR: ocrelizumab.

From American Board of Internal Medicine (ABIM)¹⁵:^aBCD19+ normal range: 208–590 cell/mm³.^bTCD4+ normal range: 530–1570 cell/mm³.^cTCD8+ normal range: 430–1060 cell/mm³.^dIgG normal range: 800–1500 g/L.^eIgA normal range: 90–325 g/L.^fIgM normal range: 45–150 g/L.

analyses, none of the previous variables were identified as independent predictors. In the whole cohort, the evidence of inflammatory activity (clinical relapse and/or MRI activity) between the two ALM courses was associated with higher risk of MRI activity during OCR ($p=0.03$), while a trend was noted for risk of clinical relapse ($p=0.08$). The same variable was associated with higher risk of relapse, MRI activity, and NEDA-3 status loss in the RRMS subgroup ($p=0.02$, $p=0.05$, $p=0.01$, respectively).

Discussion

We herein provide safety and effectiveness data about OCR treatment in MS patients who showed persistence of disease activity, both in terms of inflammation and disability progression after the first two ALM courses, retrospectively followed in a real-world multi-center Italian setting for a mean FU of almost 2.5 years.

The treatment strategy after ALM is still a matter of debate, with extension studies of pivotal trials that reported efficacy and safety of additional ALM courses^{5,6,21} and only case reports that described outcomes of switching to other disease modifying therapies (DMTs), mainly anti-CD20 depleting agents.^{8,22–25} In our study, MS severity after ALM in some patients, the radiological and immunological characteristics at the re-activation in others (multiple ring-enhancing lesions, BCD19+ cells lymphocytosis), the rapid disability worsening, and the concomitance of likely B-cell-mediated secondary autoimmunity after ALM²⁶ have been the main reasons behind the switch to OCR.

Regarding IARs, we did not observe any critical issues. In most cases (10.9%), OCR-related IARS were limited to inductive infusions, moderate in severity and completely resolved with common symptomatic therapies. In line with phase 2 and 3 clinical trials²⁷ and the few real-world studies available,^{28,29} most infectious events occurred within the first year of treatment²⁸ and a slightly increased risk of AEs among real-life PMS patients was noted in our study.^{28,30} Upper respiratory tract infections represented the most frequently observed AEs. None of the patients developed severe forms of COVID-19 disease. These reassuring findings seem to find a possible explanation in the dynamics of lymphocyte subpopulations during OCR. Indeed, the significant reduction in total lymphocyte count observed at 6- and 12-month FU was clearly driven, as expected, by B-cell depletion. Although CD20+ T cells have been




Figure 2. (a) Total lymphocytes, lymphocytes subpopulations and (b) immunoglobulins at OCR start, 6 and 12 months FU.




Figure 3. (a–h) Results of the efficacy aims for the whole cohort, RRMS, and PMS (PnoR + RP) are reported separately.

recently described as targets of OCR treatment,^{31,32} we did not observe a significant decrease in T cells counterparts during OCR therapy. Conversely, although these data were available only for patients' subgroups, we observed a trend toward an increase in TCD4+ and TCD8+ lymphocytes during the first

year FU, which became significant between 1- and 2-year FU.

Conversely, we observed a significant decrease in IgM levels between OCR start and 6 months FU. Our data exceed the percentage of IgM

Table 4. Univariate and multivariate analyses of factors associated with efficacy (whole cohort and RRMS subgroup).

	Disability worsening			MRI-inflammatory activity			Relapse			NEDA-3 status		
	HR (95% CI)	p-value	HR (95% CI)	HR (95% CI)	p-value	HR (95% CI)	HR (95% CI)	p-value	HR (95% CI)	HR (95% CI)	p-value	
Total cohort (n = 72)												
Age (at OCR start)	1.01 (0.96–1.07)	0.54	0.96 (0.88–1.05)	0.43	0.01 (0.92–0.11)	0.87	1.01 (0.96–1.07)	0.56				
Gender, female/male	0.35 (0.11–1.05)	0.06	0.87 (0.19–3.91)	0.86	0.93 (0.16–5.59)	0.94	0.53 (0.22–1.28)	0.16				
Disease duration	1.06 (0.99–1.14)	0.09	0.93 (0.81–1.07)	0.38	0.94 (0.79–1.11)	0.46	1.03 (0.96–1.09)	0.39				
EDSS (at OCR start)	1.42 (1.06–1.92)	0.02	0.82 (0.55–1.21)	0.31	0.87 (0.56–1.36)	0.55	1.16 (0.93–1.45)	0.18				
Switch to OCR (inflammatory activity/progression)	0.17 (0.05–0.59)	0.005	— ^a	— ^a	— ^a	— ^a	0.45 (0.14–1.41)	0.17				
Wash-out II ALM course-OCR start	0.98 (0.93–1.04)	0.58	1.01 (0.94–1.08)	0.82	0.99 (0.91–1.08)	0.91	0.99 (0.95–1.04)	0.81				
Time interval MS re-activation after II ALM-OCR start	0.99 (0.88–1.11)	0.86	0.87 (0.67–1.12)	0.29	0.91 (0.71–1.17)	0.48	0.96 (0.86–1.07)	0.47				
Inflammatory activity between I and II ALM courses (yes/no)	1.34 (0.45–4.01)	0.60	0.09 (0.01–0.79)	0.03	1.15 (0.02–1.31)	0.08	0.53 (0.21–1.31)	0.17				
RRMS (n = 57)												
Age (at OCR start)	1 (0.93–1.08)	0.96	0.98 (0.89–1.08)	0.73	1.03 (0.93–1.14)	0.52	1.01 (0.94–1.07)	0.84				
Gender, female/male	0.31 (0.07–1.29)	0.11	0.75 (0.17–3.37)	0.75	0.81 (0.14–4.88)	0.82	0.54 (0.18–1.53)	0.24				
Disease duration	1.08 (0.98–1.19)	0.10	0.96 (0.84–1.11)	0.61	0.97 (0.82–1.14)	0.72	1.03 (0.96–1.12)	0.39				
EDSS (at OCR start)	1.27 (0.84–1.89)	0.25	0.98 (0.63–1.52)	0.92	1.07 (0.64–1.79)	0.79	1.12 (0.83–1.53)	0.46				
Switch to OCR (inflammatory activity/progression)	— ^b	— ^b	— ^b	— ^b	— ^b	— ^b	— ^b	— ^b				
Wash-out II ALM course-OCR start	0.95 (0.88–1.02)	0.18	1.01 (0.94–1.07)	0.87	0.99 (0.91–1.08)	0.87	0.98 (0.94–1.03)	0.53				
Time interval MS re-activation after II ALM-OCR start	0.95 (0.78–1.15)	0.58	0.90 (0.71–1.14)	0.38	0.94 (0.75–1.17)	0.56	0.92 (0.79–1.07)	0.29				
Inflammatory activity between I and II ALM courses (yes/no)	0.68 (1.17–2.74)	0.58	0.08 (0.01–0.64)	0.02	0.12 (0.01–1.07)	0.05	0.26 (0.08–0.78)	0.01				

RRMS: relapsing-remitting multiple sclerosis; MRI: magnetic resonance imaging; NEDA-3: no evidence of disease activity; n: number; HR: hazard ratio; CI: confidence interval; OCR: ocrelizumab; EDSS: Expanded Disability Status Scale; ALM: alemtuzumab; MS: multiple sclerosis.
^aNo MS patients who switched for disease progression exhibited MRI inflammatory activity and/or relapses.
^bNo RRMS patients switched for disability progression.

hypogammaglobulinemia previously reported.²⁸ Nevertheless, the fact that ALM may change immunoglobulin levels (IgM more than IgG) in peripheral blood of MS patients, has been previously described.³³ The ALM-induced anti-inflammatory environment³³ and the impact of ALM on CD25+ long-lived plasma cells³⁴ have been suggested as possible explanations for delayed hypogammaglobulinemia after ALM. Speculatively, we might hypothesize a combined effect of ALM and OCR in the development of IgM hypogammaglobulinemia in our cohort. Notably, no significant correlations between TCD4+, TCD8+ lymphopenia and Ig (IgG, IgA, and IgM) levels at OCR follow-ups and infection rates were detected in our study. However, the relatively short FU may not have allowed to observe the impact of IgM hypogammaglobulinemia on IgG levels and the correspondent, although debated,³⁰ infectious risk throughout OCR treatment.

It is known that ALM causes rapid B-cell depletion with recovery to normal values after 6 months followed by a further rise of mainly naive B cells associated with a more pronounced T-reg phenotype.^{9,35–37} B-cell hyper population, when a complete and appropriate T-cell regulation is still lacking, might predispose ALM-treated patients to secondary autoimmunities.^{35,37} In such a scenario, a targeted B-cell depletion strategy has been recently attempted in a very small cohort of patients.¹⁰ Our study seemed to confirm these preliminary findings. Indeed, no patients developed secondary autoimmune complications during established OCR treatment. Furthermore, a beneficial effect of OCR was evident in patients with pre-existing ALM-related autoimmune thyroid disease. Unfortunately, the lack of a control group of patients re-treated with ALM represents a limitation of this study. Nevertheless, an indirect comparison may be made by using data from the extension phases of ALM pivotal trials³⁸ where an undoubtedly higher incidence of thyroid autoimmunity (the most common after ALM) at years 3–6 has been reported (in particular, an exposure-adjusted incidence rate per 100 patient-years of 10%).

As far as efficacy is concerned, in the RRMS population we observed that, at 2-year FU, 92.1%, 90.8%, and 94% patients were free of relapses, MRI activity, and disability worsening, respectively, with an overall percentage of patients achieving NEDA-3 of 82.1%. As per the progressive cohort (including both PnoR and RP MS patients), we observed a sustained beneficial effect of OCR treatment in terms of disability worsening and NEDA-3 status at 2-year FU (72.7%

for both). Our findings are in line with real-world evidence on OCR efficacy in RRMS,^{28,29} while we found a better performance of OCR in PMS patients than that described in a recent paper by Loreface *et al.*²⁹ The different composition of study population, fully characterized by primary progressive (PP) MS patients, may explain the discrepancy with respect to our study, in which 10/15 (66.7%) PMS patients were represented by RP patients.

Interestingly, the evidence of inflammatory activity between the first and second ALM courses was the unique variable associated with higher risk of MRI activity during OCR in the whole cohort. Similarly, the same variable was the only one associated with higher risk of relapse, MRI activity, and NEDA-3 status loss in the RRMS subgroup. Our findings are in line with those reported in core and extension phases of ALM trials^{5,6,39} and real-world evidence.⁴⁰ Through the 4-year ALM extension study, a notable percentage of “early relapsers” (i.e. patients who relapsed between the first and second ALM course: 46% in CARE-MS I(6) and 60% in CARE-MS II(5)) received a third or subsequent courses of ALM. In the Italian study by Russo *et al.*,⁴⁰ 13.9% of patients experienced a relapse between the first two ALM courses, and this was linked to higher annualized relapse rate (ARR) during the remaining FU. On the contrary, in our study, the presence of inflammatory events (clinical and/or radiological) between the first two ALM courses seemed not to impact on the risk of disability worsening during OCR treatment. Although these findings seemed to be in line with 6-year FU data about ALM “early relapsers,”³⁹ we need a longer FU to confirm this statement in our population. In conclusion, we advise focusing the attention on patients who show signs of inflammatory activity between the first two ALM courses, suggesting that a de-escalation approach to low-efficacy DMTs as rescue strategy after ALM, may be hazardous.

Our study has several limitations, including the heterogeneity linked to its multi-center setting, the relatively short FU and the availability of blood samples only for patients' subgroups, also for the concomitance of Sars-Cov2 pandemic. Further prospective studies are needed to investigate whether the switch to OCR may be preferable to additional ALM re-treatments in patients who show persistence of disease activity after the first two ALM courses.

Conclusion

The switch to OCR after the first two ALM courses seemed to have a good safety and efficacy profile. We

did not observe significant differences in terms of infections with respect to clinical trials and available real-life data. Notably, a relevant proportion of patients developed early IgM hypogammaglobulinemia after OCR initiation, but longer FU is needed to assess its impact on infectious risk. Finally, OCR treatment seemed to play a relevant role in preventing ALM-related secondary autoimmune complications. A very good performance of OCR both in terms of relapses, MRI activity, and NEDA-3 achievement was observed in RRMS and PMS populations, even if an alert must be placed on patients who show inflammatory activity between the first two ALM courses.

Acknowledgment

This work was developed thanks to the support from (1) the Italian Ministry of Health—Ministero della Salute (Rete delle Neuroscienze e della Neuroriabilitazione; Ricerca Corrente RRC 2022–2024; 5 × 1000 public funding 2017); (2) Fondazione Italiana Sclerosi Multipla Project 2020/R-Single/027; and (3) #NEXTGENERATIONEU (NGEU) of the Ministry of University and Research (MUR), National Recovery and Resilience Plan (NRRP), project MNESYS (PE0000006)—A Multiscale integrated approach to the study of the nervous system in health and disease (DN. 1553 11.10.2022).

Data availability statement

Data are available upon reasonable request from the corresponding author.

Declaration of Conflicting Interests

The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: C. Lapucci has received honoraria for speaking, travel grants, and for participating in the advisory board from Merck, Sanofi, Novartis, Roche, Alexion. J. Frau served on scientific advisory boards for Biogen and Genzyme, and has received honoraria as a speaker from Merck Serono, Genzyme, Biogen, and Teva. E. Cocco reported grants, personal fees, and non-financial support from Biogen and Merck; personal fees and non-financial support from Novartis; grants from Roche; and personal fees from Genzyme. G. Coghe received honoraria for consultancy or speaking from Biogen, Novartis, Sanofi, Genzyme, Serono, Teva, and Almirall. M. Petracca has received travel/meeting expenses from Novartis, Janssen, Roche, and Merck; speaking honoraria from HEALTH&LIFE S.r.l., AIM Education S.r.l., Biogen, Novartis, and FARECOMUNICAZIONE E20; honoraria for consulting services and advisory board participation from Biogen; research grants from Baroni Foundation and the Italian Ministry of University and Research. R.

Lanzillo has received honoraria from Biogen, Merck, Novartis, Roche, and Teva. V. Brescia Morra has received research grants from the Italian MS Society and Roche, and honoraria from Bayer, Biogen, Merck, Mylan, Novartis, Roche, Sanofi-Genzyme, and Teva. C.G. Nicoletti received travel funding from Biogen, Merck Serono, Sanofi-Genzyme, Roche, Teva, Novartis, Bristol Mayer Squibb, Janssen, Almirall and consultation fees from Sanofi, Almirall, Merck-Serono, Roche, Novartis, and Biogen. She is a sub-investigator in clinical trials being conducted for Biogen, Merck Serono, Roche, Biogen, Sanofi, Novartis, Teva, Bristol Mayer Squibb. D. Landi has received travel funding from Biogen, Merck Serono, Sanofi, Teva, Bristol Myers Squibb, Mylan; speaking or consultations fees from Sanofi, Merck Serono, Teva, Biogen, Roche, Novartis, Bristol Myers Squibb, Bayer-Schering. G. Marfia has received travel funding, speaking or consultation fees from Almirall, Bayer-Schering, Biogen, Sanofi, Merck Serono, Novartis, Teva, Mylan, Bristol Mayers Squibb and research grants from Roche and Biogen. M. Vercellino has received congress grants, speaker fees and advisory board fees from Merck-Serono, Novartis, Roche, Biogen, Sanofi Genzyme. P. Cavalla has received honoraria as speaker or travel grants to attend national and international conferences or consultation for advisory boards from Alexion, Almirall, Bayer Schering, Biogen, Cellgene-BMS, Merck-Serono, Teva, Roche, Novartis, Sanof-Genzyme, and Janssen. A. Bianco has received honoraria for speaking, advisory board/consulting from Biogen, Novartis, Merck Serono, Roche, Sanofi Genzyme. M. Mirabella has received honoraria for speaking, advisory board/consulting from Biogen, Novartis, Merck Serono, Roche, Almirall, Sanofi Genzyme, Janssen, Bristol-Myers Squibb, Viatrix, Alexion. He is principal investigator in clinical trials for Biogen, Merck Serono, Novartis, Roche, Sanofi Genzyme, CSL Behring, Ultragenix, Argenx. V. Torri Clerici acted as an Advisory Board member of Biogen Idec, Novartis, Merck Serono, Roche, Sanofi Genzyme, Almirall, Lundbeck and Bristol Myers Squibb; she received funding for traveling and honoraria for speaking or writing from Novartis, Sanofi Genzyme, Horizon, Merck Serono, Roche, Bristol Myers Squibb, Janssen and Almirall. She received support for research project by Almirall. E. Tomas received funding for work contract from Roche. M.T. Ferrò has received consultancy fees or speaker compensation from Sanofi, Bristol, Biogen Idec, and Novartis. L. Moiola has received honoraria for speaking and for participating in advisory board from Merck, Celgene, Biogen, Sanofi, Novartis, Roche, Alexion. M. Zaffaroni has received advisory board membership, speakers honoraria, travel support, research grants, consulting fees or clinical trial support


from Actelion, Almirall, Bayer Schering, Biogen, Celgene, Excemed, Genzyme, Merck, Novartis, Sanofi, Roche, Teva. M. Ronzoni has received travel grants for congresses participation from Biogen, Genzyme, Novartis e Merck. G. Novi has received speaker honoraria from Merck, Novartis, Roche, Alexion. M. Cellerino has received consulting fees from Novartis, Genzyme, Teva and Zambon. A. Uccelli has received grants (to his institution) from FISM, Biogen, Roche, Alexion, and Merck Serono and has participated on a data safety monitoring board or advisory board (to his institution) for BD, Biogen, Iqvia, Sanofi, Roche, Alexion, and Bristol Myers Squibb. M. Inglese received grants from NIH, NMSS, and FISM; received fees for consultation from BMS, Janssen, Roche, Genzyme, Merck, Biogen and Novartis. P. Grossi, A. Nozzolillo, and F. Pinardi have nothing to disclose.


Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

ORCID iDs

Eleonora Cocco  <https://orcid.org/0000-0002-3878-8820>

Maria Petracca  <https://orcid.org/0000-0001-9429-2769>

Paola Cavalla  <https://orcid.org/0000-0003-4589-4864>

Massimiliano Mirabella  <https://orcid.org/0000-0002-7783-114X>

Lucia Moiola  <https://orcid.org/0000-0001-6313-4952>

Giovanni Novi  <https://orcid.org/0000-0003-3877-6763>

References

1. Simpson A, Mowry EM and Newsome SD. Early aggressive treatment approaches for multiple sclerosis. *Curr Treat Options Neurol* 2021; 23(7): 19.
2. Iaffaldano P, Lucisano G, Caputo F, et al. Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or escalation treatment strategies. *Ther Adv Neurol Disord*. Epub ahead of print 31 May 2021. DOI: 10.1177/17562864211019574.
3. Boffa G, Massacesi L, Inglese M, et al. Long-term clinical outcomes of hematopoietic stem cell transplantation in multiple sclerosis. *Neurology* 2021; 96(8): e1215–e1226.
4. Syed YY. Alemtuzumab: A review in relapsing remitting multiple sclerosis. *Drugs* 2021; 81(1): 157–168.
5. Coles AJ, Cohen JA, Fox EJ, et al. Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings. *Neurology* 2017; 89(11): 1117–1126.
6. Havrdova E, Arnold DL, Cohen JA, et al. Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy. *Neurology* 2017; 89(11): 1107–1116.
7. Saxena G, Moore JM, Jones M, et al. Detecting and predicting neutralization of alemtuzumab responses in MS. *Neurol Neuroimmunol Neuroinflamm* 2020; 7(4): e767.
8. Adamec I and Habek M. Ocrelizumab for post-alemtuzumab paradoxical disease activity in highly active multiple sclerosis. *Clin Neuropharmacol* 2022; 45(5): 139–141.
9. Signoriello E, Lus G, Saccà F, et al. Alemtuzumab-related lymphocyte subset dynamics and disease activity or autoimmune adverse events: Real-world evidence. *J Clin Med* 2023; 12(5): 1768.
10. Meltzer E, Campbell S, Ehrenfeld B, et al. Mitigating alemtuzumab-associated autoimmunity in MS: A “whack-a-mole” B-cell depletion strategy. *Neurol Neuroimmunol Neuroinflamm* 2020; 7(6): e868.
11. Horáková D, Boster A, Bertolotto A, et al. Proportion of alemtuzumab-treated patients converting from relapsing-remitting multiple sclerosis to secondary progressive multiple sclerosis over 6 years. *Mult Scler J Exp Transl Clin*. Epub ahead of print 18 December 2020. DOI: 10.1177/2055217320972137.
12. Lublin FD, Reingold SC, Cohen JA, et al. Defining the clinical course of multiple sclerosis: The 2013 revisions. *Neurology* 2014; 83(3): 278–286.
13. Tazza F, Lapucci C, Cellerino M, et al. Personalizing ocrelizumab treatment in Multiple Sclerosis: What can we learn from Sars-Cov2 pandemic? *J Neurol Sci* 2021; 427: 117501.
14. Brownlee W, Bourdette D, Broadley S, et al. Treating multiple sclerosis and neuromyelitis optica spectrum disorder during the COVID-19 pandemic. *Neurology* 2020; 94(22): 949–952.
15. American Board of Internal Medicine (ABIM), <https://www.abim.org/Media/bfjryql/laboratory-reference-ranges.pdf> (version January 2024).
16. Ocrelizumab-Riassunto delle Caratteristiche del Prodotto, https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdffileName=footer_004768_045889_RCP.pdf&retry=0&sys=m0b113
17. Koch MW, Moral E, Brieva L, et al. Relapse recovery in relapsing-remitting multiple sclerosis: An analysis of the CombiRx dataset. *Mult Scler* 2023; 29(14): 1776–1785.

18. Wiendl H and Meuth SG. Pharmacological approaches to delaying disability progression in patients with multiple sclerosis. *Drugs* 2015; 75(9): 947–977.
19. Caon C, Namey M, Meyer C, et al. Prevention and management of infusion-associated reactions in the Comparison of Alemtuzumab and Rebif[®] Efficacy in Multiple Sclerosis (CARE-MS) Program. *Int J MS Care* 2015; 17(4): 191–198.
20. CFR – Code of Federal Regulations title 21, <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm?fr=312.32>
21. Coles AJ, Achiron A, Traboulsee A, et al. Safety and efficacy with alemtuzumab over 13 years in relapsing-remitting multiple sclerosis: Final results from the open-label TOPAZ study. *Ther Adv Neurol Disord*. Epub ahead of print 21 September 2023. DOI: 10.1177/17562864231194823.
22. Brannigan J, Jones JL and Stacpoole SRL. Severe paradoxical disease activation following alemtuzumab treatment for multiple sclerosis. *Neurol Neuroimmunol Neuroinflamm* 2020; 7(5): e799.
23. Wehrum T, Beume L-A, Stich O, et al. Activation of disease during therapy with alemtuzumab in 3 patients with multiple sclerosis. *Neurology* 2018; 90(7): e601–e605.
24. Haghikia A, Dendrou CA, Schneider R, et al. Severe B-cell-mediated CNS disease secondary to alemtuzumab therapy. *Lancet Neurol* 2017; 16(2): 104–106.
25. Rinaldi F, Federle L, Puthenparampil M, et al. Evidence of B-cell dysregulation in severe CNS inflammation after alemtuzumab therapy. *Neurol Neuroimmunol Neuroinflamm* 2018; 5(1): e420.
26. Steinman L. Induction of new autoimmune diseases after alemtuzumab therapy for multiple sclerosis: Learning from adversity. *JAMA Neurol* 2017; 74(8): 907–908.
27. Hauser SL, Bar-Or A, Comi G, et al. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. *N Engl J Med* 2017; 376(3): 221–234.
28. Cellerino M, Boffa G, Lapucci C, et al. Predictors of ocrelizumab effectiveness in patients with multiple sclerosis. *Neurotherapeutics* 2021; 18(4): 2579–2588.
29. Loreface L, Mellino P, Frau J, et al. Ocrelizumab use in multiple sclerosis: A real-world experience in a changing therapeutic scenario. *Neurol Sci*. Epub ahead of print 12 March 2024. DOI: 10.1007/s10072-024-07449-0.
30. Seery N, Sharmin S, Li V, et al. Predicting infection risk in multiple sclerosis patients treated with ocrelizumab: A retrospective cohort study. *CNS Drugs* 2021; 35(8): 907–918.
31. Gingele S, Jacobus TL, Konen FF, et al. Ocrelizumab depletes CD20+ T cells in multiple sclerosis patients. *Cells* 2018; 8(1): 12.
32. Schuh E, Berer K, Mulazzani M, et al. Features of human CD3+CD20+ T cells. *J Immunol* 2016; 197(4): 1111–1117.
33. Möhn N, Pfeuffer S, Ruck T, et al. Alemtuzumab therapy changes immunoglobulin levels in peripheral blood and CSF. *Neurol Neuroimmunol Neuroinflamm* 2020; 7(2): e654.
34. Kumar S, Kimlinger TK, Lust JA, et al. Expression of CD52 on plasma cells in plasma cell proliferative disorders. *Blood* 2003; 102(3): 1075–1077.
35. Von Essen MR, Chow HH, Holm Hansen R, et al. Immune reconstitution following alemtuzumab therapy is characterized by exhausted T cells, increased regulatory control of proinflammatory T cells and reduced B cell control. *Front Immunol* 2023; 14: 1249201.
36. Rolla S, De Mercanti SF, Bardina V, et al. Long-term effects of alemtuzumab on CD4+ lymphocytes in multiple sclerosis patients: A 72-month follow-up. *Front Immunol* 2022; 13: 818325.
37. Kashani N, Kelland EE, Vajdi B, et al. Immune regulatory cell bias following alemtuzumab treatment in relapsing-remitting multiple sclerosis. *Front Immunol* 2021; 12: 706278.
38. Coles AJ, Arnold DL, Bass AD, et al. Efficacy and safety of alemtuzumab over 6 years: Final results of the 4-year CARE-MS extension trial. *Ther Adv Neurol Disord*. Epub ahead of print 23 April 2021. DOI: 10.1177/1756286420982134.
39. Van Wijmeersch B, Singer BA, Boster A, et al. Efficacy of alemtuzumab over 6 years in relapsing-remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies. *Mult Scler* 2020; 26(13): 1719–1728.
40. Russo CV, Saccà F, Frau J, et al. A real-world study of alemtuzumab in a cohort of Italian patients. *Eur J Neurol* 2022; 29(1): 257–266.